THOX.F Stock Overview
An in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BioPorto A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.0.31 |
| 52 Week High | kr.0.43 |
| 52 Week Low | kr.0.21 |
| Beta | 1.19 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -61.25% |
| 5 Year Change | n/a |
| Change since IPO | -27.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| THOX.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.6% | 1.6% |
| 1Y | n/a | 7.0% | 26.1% |
Return vs Industry: Insufficient data to determine how THOX.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how THOX.F performed against the US Market.
Price Volatility
| THOX.F volatility | |
|---|---|
| THOX.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: THOX.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine THOX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | 29 | Peter Eriksen | bioporto.com |
BioPorto A/S, an in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated clinical chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. BioPorto A/S was incorporated in 1917 and is based in Hellerup, Denmark.
BioPorto A/S Fundamentals Summary
| THOX.F fundamental statistics | |
|---|---|
| Market cap | US$67.55m |
| Earnings (TTM) | -US$8.08m |
| Revenue (TTM) | US$4.44m |
15.2x
P/S Ratio-8.4x
P/E RatioIs THOX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THOX.F income statement (TTM) | |
|---|---|
| Revenue | kr.30.96m |
| Cost of Revenue | kr.10.78m |
| Gross Profit | kr.20.18m |
| Other Expenses | kr.76.51m |
| Earnings | -kr.56.33m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 65.19% |
| Net Profit Margin | -181.95% |
| Debt/Equity Ratio | 0% |
How did THOX.F perform over the long term?
See historical performance and comparison